SPCC (Sharing Progress in Cancer Care) shared a post on LinkedIn:
“What guides clinical decisions in today’s MBC landscape? Which first-line strategies are available according to ESMO guidelines, and what lies beyond the guidelines, including TNBC, HER2-low, and ultralow?
Our recent webinar, ‘The urgency to treat with the best treatment options in the first-line MBC setting’, is now available free of charge on OncoCorner in the Prevention and Treatment section (registration required).
In this session, you will gain insights into:
- The patient advocate perspective
- The continuum from TNBC to HR+/HER2−: aggressiveness, risk, and personalised clinical strategies
- How to approach first-line MBC in daily practice
With:
- Tanja Spanic, EUROPA DONNA – The European Breast Cancer Coalition, Slovenia
- Evandro de Azambuja, Université libre de Bruxelles, Hôpital Universitaire de Bruxelles and Institut Jules Bordet Belgium
- Esther Sanfeliu Torres, Biomedical Diagnostic Centre (CDB), Hospital Clínic de Barcelona, Spain
Watch the full webinar now.
This activity is supported by Gilead Sciences Europe Ltd.”
More posts featuring SPPC.